Newtyn Management, LLC Arca Biopharma, Inc. Transaction History

Newtyn Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.7 - $2.05 $52,156 - $62,893	-30,680 Reduced 10.23%	269,320 $457,000
Q3 2023 Nov 14, 2023	SELL	$2.01 - $2.07 $26,531 - $27,323	-13,200 Reduced 4.21%	300,000 $602,000
Q2 2023 Aug 14, 2023	SELL	$1.94 - $2.11 $400,736 - $435,852	-206,565 Reduced 39.74%	313,200 $635,000
Q1 2023 May 15, 2023	SELL	$1.99 - $2.55 $36,840 - $47,208	-18,513 Reduced 3.44%	519,765 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$1.86 - $25.8 $71,197 - $987,572	38,278 Added 7.66%	538,278 $1.28 Million
Q3 2022 Nov 14, 2022	BUY	$2.13 - $25.68 $1.07 Million - $12.8 Million	500,000 New	500,000 $1.03 Million

280K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.